Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2026
Reporting Period: Single event date (September 12, 2026)
The Company submitted a Statement of Interest to the U.S. Food and Drug Administration (FDA) requesting a Commissioner's National Priority Voucher (CNPV) for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) for the treatment of babesiosis.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a regulatory event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Progress
- Regulatory Action: Submission of a CNPV request to the FDA for tafenoquine to treat babesiosis, a tick-borne parasitic infection with no current FDA-approved therapy.
- Clinical Efficacy Signal:
- Published case reports indicate tafenoquine added to atovaquone-based therapy cured approximately 83% of relapsing patients, approaching 100% with sustained treatment.
- In the Company's FDA-authorized expanded access study (NCT06478641), all three currently evaluable patients have been cured.
- Randomized Controlled Trial (NCT06207370):
- A randomized, double-blind, placebo-controlled trial at five Northeastern hospitals.
- Enrollment for the prespecified interim analysis is complete.
- Data Safety Monitoring Board (DSMB) analysis is scheduled for October 1, 2026.
Guidance, Outlook, and Risks
Regulatory Pathway and Timeline:
- Target Submission: The Company intends to submit a supplemental New Drug Application (sNDA) in March–April 2027.
- Approval Strategy: Depending on the interim analysis outcome, the Company will pursue either regular approval (supported by the randomized trial) or accelerated approval (supported by expanded-access and published evidence).
- Strategic Goal: Securing a CNPV could enable approval by or before the 2027 tick season. Standard review timelines would likely extend approval beyond the 2027 season.
Commitments:
- Commitment to manufacture more than 50% of the value of future CNPV-supported products in the United States.
- Commitment to provide volume-based discounts to federal programs.
Risks and Contingencies:
- Uncertainty regarding the FDA's acceptance of the CNPV request.
- Outcomes of the DSMB interim analysis and the randomized controlled trial.
- Sufficiency of clinical data to support regulatory approval.
- Availability of funding for development and commercialization.
- Manufacturing capabilities for commercial distribution.
Investor Verification Checklist
- Verify the FDA's decision on the Commissioner's National Priority Voucher (CNPV) request.
- Monitor the results of the DSMB interim analysis scheduled for October 1, 2026.
- Confirm the final regulatory pathway (regular vs. accelerated approval) following the interim analysis.
- Track the actual sNDA submission date relative to the March–April 2027 target.
- Assess the Company's cash runway and funding status given the lack of current revenue data in this filing.